Amplia Therapeutics Limited (ATX.AX)

0.0640 +0.0030 (+4.92%) At close: 04:10PM AEST

Amplia Therapeutics Limited

350 Queen Street
Level 17
Melbourne, VIC 3000
Australia
61 3 9123 1140
https://www.ampliatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.	CEO, MD & Director	377.81k	N/A	1965
Mr. Tim Luscombe B.Com., C.A.	Chief Financial Officer	N/A	N/A	N/A
Ms. Rhiannon Jones B.Sc., Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD	Company Secretary	76.67k	N/A	1960

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Amplia Therapeutics Limited, a pharmaceutical company, focuses on the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline includes AMP945, an inhibitor of FAK that has completed Phase I clinical trial for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases; and AMP886 for treating acute myeloid leukemia and various solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Corporate governance

Amplia Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.